[go: up one dir, main page]

PE20150735A1 - Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson - Google Patents

Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson

Info

Publication number
PE20150735A1
PE20150735A1 PE2015000364A PE2015000364A PE20150735A1 PE 20150735 A1 PE20150735 A1 PE 20150735A1 PE 2015000364 A PE2015000364 A PE 2015000364A PE 2015000364 A PE2015000364 A PE 2015000364A PE 20150735 A1 PE20150735 A1 PE 20150735A1
Authority
PE
Peru
Prior art keywords
parkinson
depression
disease
treatment
pirazole
Prior art date
Application number
PE2015000364A
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20150735A1 publication Critical patent/PE20150735A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Referida a compuestos de la formula (I), donde: R1 es fenilo, alquilo C1-C7, cicloalquilo C3-C6, alcoxi C1-C7, ciano, entre otros; R2 es hidrogeno o alquilo C1-C7; R3 es hidrogeno, amino o alquilo C1-C7; Z es un enlace, -CH2- u -O-; o a una sal de adicion de acido farmaceuticamente adecuada de los mismos. Dichos compuestos tienen afinidad con los receptores asociados con las aminas traza (TAAR), en especial con el TAAR1 y son utiles en el tratamiento de la depresion, los trastornos de ansiedad, el trastorno bipolar, el trastornos de hiperactividad con deficit de atencion (ADHD), los trastornos relacionados con el estres, los trastornos psicoticos, la esquizofrenia, las enfermedades nuerologicas, la enfermedad de Parkinson, entre otros
PE2015000364A 2012-09-14 2013-09-11 Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson PE20150735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12184360 2012-09-14

Publications (1)

Publication Number Publication Date
PE20150735A1 true PE20150735A1 (es) 2015-05-17

Family

ID=47044779

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000364A PE20150735A1 (es) 2012-09-14 2013-09-11 Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson

Country Status (35)

Country Link
US (1) US9487501B2 (es)
EP (1) EP2895477B1 (es)
JP (2) JP2015531782A (es)
KR (1) KR101706486B1 (es)
CN (2) CN107903251A (es)
AR (1) AR092537A1 (es)
AU (1) AU2013314388B2 (es)
BR (1) BR112015004511B1 (es)
CA (1) CA2882821C (es)
CL (1) CL2015000580A1 (es)
CR (1) CR20150087A (es)
DK (1) DK2895477T3 (es)
EA (1) EA026062B1 (es)
ES (1) ES2654653T3 (es)
HK (2) HK1206720A1 (es)
HR (1) HRP20171981T1 (es)
HU (1) HUE037689T2 (es)
IL (1) IL237332B (es)
LT (1) LT2895477T (es)
MA (1) MA37944B2 (es)
MX (1) MX363362B (es)
MY (1) MY178667A (es)
NO (1) NO2895477T3 (es)
NZ (1) NZ705154A (es)
PE (1) PE20150735A1 (es)
PH (1) PH12015500489B1 (es)
PL (1) PL2895477T3 (es)
PT (1) PT2895477T (es)
RS (1) RS56747B1 (es)
SG (1) SG11201501958QA (es)
SI (1) SI2895477T1 (es)
TW (1) TWI610926B (es)
UA (1) UA113776C2 (es)
WO (1) WO2014041007A1 (es)
ZA (1) ZA201501126B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174853B1 (en) * 2014-07-30 2018-12-12 F.Hoffmann-La Roche Ag 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as taar modulators
MX377836B (es) * 2016-03-17 2025-03-11 F Hoffmann La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida teniendo actividad como agonista de receptor asociado con aminas trazas (taar).
BR112019012263A2 (pt) * 2016-12-15 2020-01-28 Univ California composições e métodos para tratar câncer
SG11202110401WA (en) 2019-04-09 2021-10-28 Hoffmann La Roche Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2022262855A1 (zh) * 2021-06-18 2022-12-22 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
CN116236478A (zh) * 2022-12-27 2023-06-09 浙江大学 芳香杂环甲酰胺类化合物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
RU2460725C2 (ru) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2012063896A1 (ja) * 2010-11-11 2012-05-18 第一三共株式会社 新規ピラゾールアミド誘導体
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives

Also Published As

Publication number Publication date
EP2895477B1 (en) 2017-11-01
CN107903251A (zh) 2018-04-13
PH12015500489A1 (en) 2015-04-20
DK2895477T3 (en) 2018-01-15
AR092537A1 (es) 2015-04-22
EA026062B1 (ru) 2017-02-28
HRP20171981T1 (hr) 2018-02-09
ES2654653T3 (es) 2018-02-14
ZA201501126B (en) 2016-01-27
IL237332B (en) 2018-07-31
EP2895477A1 (en) 2015-07-22
LT2895477T (lt) 2018-01-25
BR112015004511A2 (pt) 2017-07-04
US9487501B2 (en) 2016-11-08
JP2017122103A (ja) 2017-07-13
CR20150087A (es) 2015-04-06
RS56747B1 (sr) 2018-03-30
SI2895477T1 (en) 2018-02-28
TWI610926B (zh) 2018-01-11
HK1206720A1 (en) 2016-01-15
MX2015002900A (es) 2015-06-03
MY178667A (en) 2020-10-20
NO2895477T3 (es) 2018-03-31
KR101706486B1 (ko) 2017-02-13
WO2014041007A1 (en) 2014-03-20
CN104619700A (zh) 2015-05-13
PT2895477T (pt) 2017-12-29
PL2895477T3 (pl) 2018-03-30
CL2015000580A1 (es) 2015-07-10
SG11201501958QA (en) 2015-04-29
BR112015004511A8 (pt) 2021-11-03
MX363362B (es) 2019-03-21
BR112015004511B1 (pt) 2022-08-02
TW201425308A (zh) 2014-07-01
US20150218131A1 (en) 2015-08-06
UA113776C2 (xx) 2017-03-10
IL237332A0 (en) 2015-04-30
NZ705154A (en) 2018-03-23
JP6529998B2 (ja) 2019-06-12
PH12015500489B1 (en) 2015-04-20
JP2015531782A (ja) 2015-11-05
HUE037689T2 (hu) 2018-09-28
AU2013314388B2 (en) 2016-07-14
AU2013314388A1 (en) 2015-03-05
CA2882821A1 (en) 2014-03-20
HK1252981A1 (zh) 2019-06-06
MA37944A1 (fr) 2016-04-29
CA2882821C (en) 2018-05-22
MA37944B2 (fr) 2017-10-31
EA201590454A1 (ru) 2015-09-30
KR20150054947A (ko) 2015-05-20

Similar Documents

Publication Publication Date Title
PE20150735A1 (es) Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson
EA201391341A1 (ru) Производные гетероциклических аминов
CO2017011174A2 (es) Derivados de etileno como moduladores metabotropicos de receptores de glutamato
EA201391787A1 (ru) Производные пиразола
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
CO6531470A2 (es) Derivados benzamida sustituidos
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20090655A1 (es) Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis
CR11843A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
AR078756A1 (es) Moduladores alostericos positivos (map)
BR112013026807A2 (pt) derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato
CL2008002293A1 (es) Compuestos derivados de aril-eteres de pirrolidina con actividad antagonista de los receptores nk-3; proceso de preparacion; composiicon farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, dolor, psicosis, parkinson, ezquizofrenia, ansiedad y trastorno de hiperactividad con deficit de atencion (adhd)
BR112015006454A8 (pt) derivados de etinila como moduladores de atividade de receptor de mglur5
CL2013003485A1 (es) Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes.
AR067075A1 (es) Derivados de isoxasol - imidazol
PE20141168A1 (es) Derivados de pirazolidin-3-ona
PH12015500346A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
AR083718A1 (es) Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500261A1 (en) Arylethynyl pyrimidines
DE602008005014D1 (de) Prolinamidtetrazolderivate als nk3-rezeptorantagonisten
MX2016016190A (es) Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.
PE20091681A1 (es) 3-indazolil-4-piridilisotiazoles

Legal Events

Date Code Title Description
FG Grant, registration